We are convinced that looking at TLS within tumors in a routine could change the therapeutic strategies for patients with sarcomas. We have only limited options for sarcomas and depending on the histotype, there is only a few targeted therapies like VEGFR inhibitors or palliative chemotherapies. Using the TLS as a biomarker offers the possibility of a good response to immune checkpoint inhibition and some patients also have long responses, so also a good quality of life...
We are convinced that looking at TLS within tumors in a routine could change the therapeutic strategies for patients with sarcomas. We have only limited options for sarcomas and depending on the histotype, there is only a few targeted therapies like VEGFR inhibitors or palliative chemotherapies. Using the TLS as a biomarker offers the possibility of a good response to immune checkpoint inhibition and some patients also have long responses, so also a good quality of life. So this is a really interesting strategy for these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
